Church & Dwight posted solid Q2 2026 organic growth and raised guidance, but the stock already reflects much of the good news. With shares near fair value, the report lands on a Hold.
Church & Dwight Company Inc (CHD) offers a strong medium-term business story built on trusted brands, recurring consumer demand, volume-led growth, and disciplined innovation. The Q2 2026 results support that view: organic sales rose 5.8%, volume increased 4.3%, adjusted EPS reached $0.89, and management raised its full-year organic sales, adjusted EPS, and cash-flow outlook.
The investment case is not a bargain case. CHD trades near $106.00, at 33.5x trailing earnings and 25.8x forward earnings. The PEG ratio of 2.9 also shows that the share price already reflects a meaningful premium to the company’s roughly mid-single-digit earnings growth profile. The business earns that premium in part through brand strength and reliable cash generation, but the valuation leaves limited room for execution errors.
The balanced conclusion is Hold for a moderate-risk investor. CHD has a credible path through THERABREATH, ARM & HAMMER cat litter, HERO, international expansion, e-commerce, and the MISS MOUTH’S acquisition. At the same time, revenue growth was only 1.6% in 2025, net debt was $1.8B at year-end, and consensus targets cluster around $105. The combination points to a high-quality company whose stock is close to its fair-value estimate of $106.00.
Founded in 1846 and headquartered in Ewing, New Jersey, Church & Dwight develops, manufactures, and markets household, personal care, and specialty products. The company had 5,550 employees and trades on the NYSE under CHD. Its portfolio includes ARM & HAMMER, OXICLEAN, BATISTE, WATERPIK, THERABREATH, HERO, TOUCHLAND, TROJAN, FIRST RESPONSE, NAIR, ORAJEL, XTRA, and ZICAM.
The business operates through Consumer Domestic, Consumer International, and Specialty Products. Consumer products reach supermarkets, mass merchants, wholesale clubs, drugstores, convenience stores, home stores, dollar stores, pet stores, specialty retailers, websites, and other e-commerce channels. Specialty products serve industrial customers, distributors, and livestock producers.
CHD is smaller and more focused than Procter & Gamble (PG), but its portfolio is broad for a company with $6.2B of annual revenue. Management says ten key brands represent about 80% of consumer sales, while ARM & HAMMER represents about 40% of domestic consumer products. That concentration creates operating leverage when leading brands gain share, but it also raises the cost of an innovation failure in a major category.
Consumer Domestic remains the largest operating engine. Q2 2026 net sales were $1.16B, up 0.1% year over year, while organic sales increased 5.1%. Organic growth came from volume growth of 3.6% and price/mix growth of 1.5%. THERABREATH, HERO, ARM & HAMMER cat litter, and ZICAM led the quarter.
Consumer International produced the strongest segment growth. Q2 net sales were $297.5M, up 7.2%, while organic sales rose 9.1%, driven by volume growth of 7.3% and price/mix growth of 1.8%. THERABREATH, HERO, and BATISTE supported growth across Europe, Asia, and Latin America. International growth outpaced local country GDP, according to management.
Specialty Products generated Q2 net sales of $76.7M and organic growth of 2.8%, with volume up 1.3% and price/mix up 1.5%. The division sells sodium bicarbonate, animal nutrition products, and specialty ingredients such as BIO-CHLOR, FERMENTEN, CELMANAX, and CERTILLUS. Its growth is slower than Consumer International, but it adds category diversity and uses CHD’s baking soda expertise beyond household products.
The segment pattern is constructive. Domestic provides scale, International supplies faster growth, and Specialty Products adds a smaller industrial and agricultural base. The main issue is reported growth: portfolio exits and strategic actions reduced the conversion of organic growth into total sales, with consolidated Q2 net sales up only 1.6%.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
ARM & HAMMER remains the foundation of CHD’s consumer franchise. Its laundry products held record shares across total laundry in Q2 even as competitor promotions increased. ARM & HAMMER cat litter consumption grew 7.5%, and market share increased 0.8 percentage points to 24.5%. The DUAL DEFENSE with Microban Clumping Litter launch adds a specific odor-control and antimicrobial proposition to a category where performance drives repeat purchases.
THERABREATH is the clearest growth platform. Consumption grew more than 20% in Q2, share increased 4.5 percentage points to 25.3%, and the brand strengthened its position as the No. 2 mouthwash franchise. Household penetration was 14% versus 65% for the mouthwash category. That gap gives the brand room to grow without relying only on higher prices.
THERABREATH toothpaste reached a 1% share of total toothpaste after only recently gaining full brick-and-mortar distribution. The company also launched THERABREATH Complete rinse and portable rinse sachets. These extensions matter because they convert a successful rinse brand into a broader oral-care platform, increasing the number of consumer occasions attached to the franchise.
HERO provides another underpenetrated growth lane. Household penetration was 10% versus 30% for the acne category, and the company expanded into facial cleansers with Mighty Cleanser, Pore Cleanser, and Gentle Cleansers. MISS MOUTH’S adds a newer stain-removal asset. Management described it as the No. 1 stain remover brand on Amazon, with consumption up more than 50% and household penetration of 2.5% versus 50% for its category.
CHD’s most important advantage is the ability to build brands in focused niches and then extend them across products, retailers, and geographies. Management said innovation and distribution gains were major contributors to industry-leading organic growth, and new product launches are expected to account for about half of 2026 organic growth.
The recent product pipeline illustrates that model. DUAL DEFENSE expands ARM & HAMMER in cat litter, THERABREATH toothpaste expands oral care, HERO cleansers broaden acne treatment, and MISS MOUTH’S adds a stain-removal brand with low household penetration. Each initiative combines an existing distribution system with a specific consumer problem.
The competitive advantage is operational as much as creative. Management highlighted speed and agility, retailer relationships, price-pack architecture, and the ability to scale acquired brands internationally. Global e-commerce grew 22.7% in Q2, reaching 25.5% of total consumer sales, giving CHD a measurable channel for testing products and building distribution.
CHD’s Q2 adjusted gross margin was 45.4%, up 40 basis points year over year. Productivity programs contributed 150 basis points, higher-margin acquisitions contributed 110 basis points, and volume, price, and mix contributed 180 basis points. Those gains offset 400 basis points of inflation, tariff, and transportation pressure.
The margin bridge shows why execution matters. CHD is not operating in a cost-free environment, but its productivity program is large enough to absorb significant external pressure. Management expects adjusted gross-margin expansion of 100 to 120 basis points for 2026 and plans to invest the benefit in marketing and consumer-facing activities.
Cash conversion is another operational strength. Cash from operations reached $462M in the first half of 2026, up 10.8% year over year. Capital expenditures were $61.8M in the first half, while full-year capital expenditures are expected to be approximately $130M, or about 2% of sales. That capital intensity leaves room for marketing, acquisitions, debt reduction, and shareholder returns.
The household-care market has a large and growing base. Market estimates place global household care products at $202.3B in 2026 and $262.5B by 2031, a 5.3% compound annual growth rate. Household cleaners are estimated at $170.5B in 2026 and $213.8B by 2031, a 4.6% compound annual growth rate.
CHD’s addressable opportunity extends beyond cleaning. Oral care, acne treatment, dry shampoo, sexual health, pet products, and specialty nutrition give the company exposure to categories with different demand drivers. The company’s own category framework assumes roughly 3% weighted average category growth, with historical share gains supporting approximately 4% organic sales growth.
The channel mix is changing quickly. Online retail is expanding faster than the broader consumer packaged goods market, and CHD’s 25.5% global online consumer-sales mix is already material. Digital shelf placement, reviews, search visibility, and replenishment behavior now influence brand growth alongside physical shelf space.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
CHD serves consumers who buy frequently used household and personal-care products, as well as industrial and agricultural customers who purchase specialty ingredients. The consumer portfolio covers both value and premium positioning. Management has described the worldwide consumer portfolio as 64% premium brands and 36% value brands, a mix that supports participation across different spending conditions.
The strongest customer opportunities are in categories where CHD combines low household penetration with strong product performance. THERABREATH has 14% household penetration against 65% for mouthwash, HERO has 10% against 30% for acne, and MISS MOUTH’S has 2.5% against 50% for stain removers. These figures give the company a concrete distribution and trial runway.
Retailers are also customers of CHD’s innovation system. Management said MISS MOUTH’S was already at a 13% share at a major retailer after only a few months. That early shelf performance gives the company a stronger negotiating position when presenting the brand alongside OXICLEAN and other fabric-care products.
The closest household-products peers include Procter & Gamble (PG), Kimberly-Clark (KMB), Colgate-Palmolive (CL), and Clorox (CLX). CHD also competes with Henkel in laundry, Philips in adjacent oral-care equipment, Haleon and Kenvue in health-related products, Unilever in personal care, and private-label brands across most categories.
CHD’s advantage over larger competitors is focus. ARM & HAMMER, THERABREATH, HERO, and other power brands target specific consumer problems and can gain shelf space through product-level innovation. Its disadvantage is scale. P&G and other mega-cap peers have larger advertising budgets, broader global distribution, and more bargaining power with retailers.
Private-label competition remains a direct risk in laundry, cleaning, and other value-sensitive categories. Q2 provided a useful test: ARM & HAMMER laundry maintained share while competitor promotions increased, and the company’s laundry promotion level was down 300 basis points. That result supports brand resilience, but it does not eliminate the need for continued innovation and disciplined pricing.
Management described consumer spending as resilient, while Q2 category consumption grew 2.7%, above the company’s approximately 2% expectation. That backdrop supports CHD because household, oral-care, and cleaning products have repeat-purchase characteristics.
The cost environment is more challenging. CHD’s 2026 outlook includes approximately $30M of raw-material, transportation, and conflict-related premiums linked to the Middle East, assuming crude oil at approximately $90 per barrel. The company expects approximately $15M of Phase 2 tariff refunds in the second half of 2026.
CHD has responded through productivity, price/mix, portfolio actions, and marketing discipline. That response supports the 100 to 120 basis-point gross-margin outlook, but the 400 basis points of Q2 cost headwinds show that supply-chain volatility can quickly pressure profitability. International exposure also adds foreign-exchange risk, while private-label competition creates additional pressure when consumers trade down.
Net debt was $1.8B at year-end, leaving Church & Dwight with manageable leverage but little room for a valuation rerating to ignore execution risk.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q2 2026 organic sales rose 5.8% and adjusted EPS reached $0.89, showing that volume-led growth is still translating into earnings power.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management raised full-year organic sales, adjusted EPS, and cash-flow guidance after a quarter that outpaced the company’s roughly mid-single-digit growth profile.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At about 33.5x trailing earnings and 25.8x forward earnings, CHD trades at a premium that leaves limited upside unless growth accelerates further.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Consensus targets cluster around $105 while the report’s fair value estimate sits at $106, reinforcing a Hold view rather than a clear buy signal.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Church & Dwight is a well-run consumer-products company with a credible growth engine. Q2 2026 showed broad-based organic growth, strong international momentum, share gains in THERABREATH and ARM & HAMMER cat litter, improving margins, and higher cash-flow guidance. The company also has a repeatable playbook: acquire focused brands, improve distribution, extend them into adjacent products, and scale them internationally.
The stock presents a different picture from the business. A 33.5x trailing P/E, 25.8x forward P/E, 2.9 PEG ratio, and price near the $104.89 consensus target leave little valuation cushion. CHD merits a premium for its brand portfolio, profitability, and cash generation, but the current price already reflects much of that quality.
For a moderate-risk investor with a medium-term horizon, Hold is the disciplined position. The company remains worth owning for durable compounding potential, but a stronger risk-reward setup would emerge closer to $95, while $80 would represent a clear dislocation. At approximately $106.00, the market is pricing CHD as a good business. The evidence supports that judgment, but not an aggressive premium.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Church & Dwight Co., Inc. (CHD) gained after a deeper-than-headline earnings beat, with stronger organic growth, margin expansion, and raised guidance. The quarter showed volume-led momentum across key brands and segments, helping support the stock’s move despite its premium valuation.
Church & Dwight Co., Inc. (CHD) gains 0.8% after reporting earnings beats, as investors react positively to the company’s latest quarterly results and outlook.
Church & Dwight Co., Inc. (CHD) gains despite an EPS miss, as revenue topped estimates and the quarter showed resilient demand, margin pressure, and a constructive outlook. This deep-dive examines the earnings mix, cash flow trends, cost headwinds, and management’s guidance for organic sales and adjusted EPS growth.